Campbell & CO Investment Adviser LLC Purchases New Stake in argenex SE $ARGX

Key Points

• Campbell & CO Investment Adviser LLC purchased a new stake in argenex SE valued at approximately $1.38 million, acquiring 2,328 shares in the first quarter.
• Institutional investors currently hold 60.32% of argenex's stock, indicating strong support from the investment community.
• Several analysts have set target prices for argenex, with a consensus target of $757.88, suggesting bullish sentiment on its future performance.

Campbell & CO Investment Adviser LLC acquired a new position in shares of argenex SE (NASDAQ:ARGX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,328 shares of the company's stock, valued at approximately $1,378,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. RTW Investments LP lifted its stake in shares of argenex by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock worth $414,201,000 after buying an additional 19,067 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in argenex by 33.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock valued at $162,585,000 after buying an additional 68,498 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in argenex by 22.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 176,450 shares of the company's stock valued at $100,063,000 after acquiring an additional 32,239 shares during the period. Point72 Asset Management L.P. acquired a new stake in argenex during the fourth quarter worth approximately $91,013,000. Finally, GAMMA Investing LLC lifted its position in argenex by 53,684.9% during the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after acquiring an additional 135,286 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ARGX shares. JMP Securities set a $699.00 target price on argenex in a research report on Wednesday, May 14th. Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a research note on Tuesday, July 8th. Guggenheim increased their price objective on argenex from $1,060.00 to $1,070.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. HC Wainwright lifted their target price on argenex from $720.00 to $774.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Morgan Stanley boosted their target price on shares of argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating and nineteen have assigned a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $757.88.

argenex Price Performance

argenex stock opened at $677.32 on Tuesday. The firm has a market cap of $41.45 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39. The stock's fifty day moving average price is $597.70 and its two-hundred day moving average price is $597.38. argenex SE has a one year low of $510.05 and a one year high of $702.24.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. Sell-side analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.